UNLABELLED: B cells are present within chronically inflamed liver tissue and recent evidence implicates them in the progression of liver disease. In addition, a large proportion of hepatic lymphomas are of B-cell origin. The molecular signals that regulate normal and malignant B-cell recruitment into peripheral tissue from blood are poorly understood, leading us to study human B-cell migration through hepatic sinusoidal endothelial cells in flow-based adhesion assays. In such assays, human blood-derived B cells were captured from shear flow without a previous rolling phase and underwent firm adhesion mediated by vascular cell adhesion molecule-1 (VCAM-1). Unlike T cells, which displayed vigorous crawling behavior on the endothelium, B cells remained static before a proportion underwent transendothelial migration mediated by a combination of intercellular adhesion molecule-1 (ICAM-1), vascular adhesion protein-1, common lymphatic endothelial and vascular endothelial receptor-1/stabilin-1, and the chemokine receptors, CXCR3 and CXCR4. B-cell lymphoma cell lines and primary malignant B cells from patients with chronic lymphocytic leukemia and marginal zone B cell lymphoma also underwent integrin-mediated firm adhesion involving ICAM-1 and/or VCAM-1 and demonstrated ICAM-1-dependent shape-change and crawling behavior. Unlike primary lymphocytes, the malignant cells did not undergo transendothelial migration, which could explain why lymphomas are frequently characterized by the intravascular accumulation of malignant cells in the hepatic sinusoids. CONCLUSION: Our findings demonstrate that distinct combinations of signals promote B-cell recruitment to the liver, suggesting the possibility of novel targets to modulate liver inflammation in disease. Certain features of lymphocyte homing are maintained in lymphoma recruitment to the liver, suggesting that therapeutic targets for lymphocyte recruitment may also prevent hepatic lymphoma dissemination.
UNLABELLED: B cells are present within chronically inflamed liver tissue and recent evidence implicates them in the progression of liver disease. In addition, a large proportion of hepatic lymphomas are of B-cell origin. The molecular signals that regulate normal and malignant B-cell recruitment into peripheral tissue from blood are poorly understood, leading us to study human B-cell migration through hepatic sinusoidal endothelial cells in flow-based adhesion assays. In such assays, human blood-derived B cells were captured from shear flow without a previous rolling phase and underwent firm adhesion mediated by vascular cell adhesion molecule-1 (VCAM-1). Unlike T cells, which displayed vigorous crawling behavior on the endothelium, B cells remained static before a proportion underwent transendothelial migration mediated by a combination of intercellular adhesion molecule-1 (ICAM-1), vascular adhesion protein-1, common lymphatic endothelial and vascular endothelial receptor-1/stabilin-1, and the chemokine receptors, CXCR3 and CXCR4. B-cell lymphoma cell lines and primary malignant B cells from patients with chronic lymphocytic leukemia and marginal zone B cell lymphoma also underwent integrin-mediated firm adhesion involving ICAM-1 and/or VCAM-1 and demonstrated ICAM-1-dependent shape-change and crawling behavior. Unlike primary lymphocytes, the malignant cells did not undergo transendothelial migration, which could explain why lymphomas are frequently characterized by the intravascular accumulation of malignant cells in the hepatic sinusoids. CONCLUSION: Our findings demonstrate that distinct combinations of signals promote B-cell recruitment to the liver, suggesting the possibility of novel targets to modulate liver inflammation in disease. Certain features of lymphocyte homing are maintained in lymphoma recruitment to the liver, suggesting that therapeutic targets for lymphocyte recruitment may also prevent hepatic lymphoma dissemination.
Authors: Mariana Silva; Ronald Kam Fai Fung; Conor Brian Donnelly; Paula Alexandra Videira; Robert Sackstein Journal: J Immunol Date: 2017-03-22 Impact factor: 5.422
Authors: Paul J Hampel; Kari G Chaffee; Rebecca L King; Douglas Simonetto; Melissa C Larson; Sara Achenbach; Timothy G Call; Wei Ding; Saad S Kenderian; Jose F Leis; Asher A Chanan-Khan; Deborah A Bowen; Michael J Conte; Susan M Schwager; Curtis A Hanson; Susan L Slager; Neil E Kay; Tait D Shanafelt; Sameer A Parikh Journal: Am J Hematol Date: 2017-10-19 Impact factor: 10.047
Authors: Abhishek Das; Gidon Ellis; Celeste Pallant; A Ross Lopes; Pooja Khanna; Dimitra Peppa; Antony Chen; Paul Blair; Geoffrey Dusheiko; Upkar Gill; Patrick T Kennedy; Maurizia Brunetto; Pietro Lampertico; Claudia Mauri; Mala K Maini Journal: J Immunol Date: 2012-09-12 Impact factor: 5.422
Authors: Elizabeth A Kuczynski; Peter B Vermeulen; Francesco Pezzella; Robert S Kerbel; Andrew R Reynolds Journal: Nat Rev Clin Oncol Date: 2019-08 Impact factor: 66.675
Authors: Hannah C Jeffery; Manjit K Braitch; Chris Bagnall; James Hodson; Louisa E Jeffery; Rebecca E Wawman; Lin Lee Wong; Jane Birtwistle; Helen Bartlett; Ansgar W Lohse; Gideon M Hirschfield; Jessica Dyson; David Jones; Stefan G Hubscher; Paul Klenerman; David H Adams; Ye H Oo Journal: Hepatol Commun Date: 2018-02-26
Authors: Daniel A Patten; Sivesh K Kamarajah; Joanne M Rose; Joseph Tickle; Emma L Shepherd; David H Adams; Chris J Weston; Shishir Shetty Journal: Sci Rep Date: 2017-12-14 Impact factor: 4.379